The mean body mass index was 29.0 ± 4.7, 83% had comorbidities (e.g., 60% arthritis/arthralgia and 31% hypertension), 90% were T1c stage prostate cancer, 96% Gleason grade of 6, the mean PSA level was 7.3 ± 3.2, and the mean time since starting active surveillance was 1.9 ± 2.2 years. The gene discussed is KLK3; the disease is prostate carcinoma.